Japan Issues Strong Warning Over Brexit
Uncertainty is bad for business and can deter investment, warns Japan in relation to eventual talks on the UK’s exit from the EU. Japan’s preferred Brexit outcome? For the UK to keep both EU law and the European Medicines Agency.
You may also be interested in...
A mutual recognition agreement between the UK and EU on equivalence of regulatory procedures and processes could provide pharmaceutical companies with some stability and continuity post-Brexit – and save them some money.
The assumption to date has been that the European Medicines Agency will have to move from its London base when the UK leaves the EU. But things may not be quite that simple.
As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.